The main immune checkpoint inhibitors currently in clinical use are antibodies that target the Programmed Death 1 (PD-1) receptor and its ligand, Programmed Death Ligand 1 (PD-L1), thereby lifting the inhibition imposed on T lymphocytes by tumor cells. This evidence concerns the gene CD274 and neoplasm.